Skip to main content
SpringerLink
Log in

Liver Metastases of Other Indications

  • Chapter
  • First Online:
Locoregional Tumor Therapy

  • 466 Accesses

Abstract

Locoregional treatment of liver metastases has been developed especially for tumors that give liver-limited metastases. For all the tumors types and especially for the less usual that are presented in this chapter, the aim is to increase the amount of the drug delivered to the tumor and to decrease systemic toxicity. On the other hand, locoregional treatment in these specific settings may help to increase the activity of the drug especially for rather orphan tumors such as melanoma and pancreatic cancer for instance. Another aim is to fight against the appearance of resistance to systemic treatment (pancreatic carcinoma, breast cancer). In aggressive diseases such as pancreatic carcinoma and melanoma, it is obvious that the indications of locoregional treatment directed to the liver should not be proposed if there is any suspicion of extrahepatic disease. This requirement is not mandatory in tumors such as breast carcinoma in which the prognosis may be linked to liver involvement. In these tumors, liver locoregional treatment could be at least considered even if there is extrahepatic disease when the liver metastases are able to rapidly shorten the survival of the patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 24.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Beger HG, Gansauge F, Büchler MW, Link KH. Intraarterial adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic cancer: significant reduction in occurrence of liver metastasis. World J Surg. 1999;23:946–9.

    Article  CAS  PubMed  Google Scholar 

  2. Cantore M, Serio G, Pederzoli P, Mambrini A, Iacono C, Pulica C, Capelli P, Lombardi M, Torri T, Pacetti P, Pagani M, Fiorentini G. Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2006;58:504–8.

    Article  CAS  PubMed  Google Scholar 

  3. Hayashibe A, Kameyama M, Shinbo M, Makimoto S. Clinical results on intra-arterial adjuvant chemotherapy for prevention of liver metastasis following curative resection of pancreatic cancer. Ann Surg Oncol. 2007;14:190–4.

    Article  PubMed  Google Scholar 

  4. Homma H, Niitsu Y. A new regional arterial infusion chemotherapy for patients with advanced pancreatic cancer. Gan To Kagaku Ryoho. 2002;29:383–9.

    PubMed  Google Scholar 

  5. Vogl TJ, Schwarz W, Eichler K, Hochmuth K, Hammerstingl R, Jacob U, Scheller A, Zangos S, Heller M. Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy. J Cancer Res Clin Oncol. 2006;132:745–55.

    Article  CAS  PubMed  Google Scholar 

  6. Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, Comella G, Ceravolo C, Miserocchi L, Mambrini A, Del Freo A, Zamagni D, Aitini E, Marangolo M. Randomised trial of gemcitabine versus flec regimen given intra-arterially for patients with unresectable pancreatic cancer. J Exp Clin Cancer Res. 2003;22:51–7.

    CAS  PubMed  Google Scholar 

  7. Ikeda O, Tamura Y, Nakasone Y, Shiraishi S, Kawanaka K, Tomiguchi S, Yamashita Y, Takamori H, Kanemitsu K, Baba H. Comparison of intrahepatic and pancreatic perfusion on fusion images using a combined SPECT/CT system and assessment of efficacy of combined continuous arterial infusion and systemic chemotherapy in advanced pancreatic carcinoma. Cardiovasc Intervent Radiol. 2007;30:912–21.

    Article  PubMed  Google Scholar 

  8. Azizi A, Naguib NN, Mbalisike E, Farshid P, Emami AH, Vogl TJ. Liver metastases of pancreatic cancer: role of repetitive transarterial chemoembolization (TACE) on tumor response and survival. Pancreas. 2011;40:1271–5.

    Article  CAS  PubMed  Google Scholar 

  9. Becker JC, Terheyden P, Kampgen E, Wagner S, Neumann C, Schadendorf D, Steinmann A, Wittenberg G, Lieb W, Brocker EB. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer. 2002;87:840–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Peters S, Voelter V, Zografos L, Pampallona S, Popescu R, Gillet M, Bosshard W, Fiorentini G, Lotem M, Weitzen R, Keilholz U, Humblet Y, Piperno-Neumann S, Stupp R, Leyvraz S. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol. 2006;17:578–83.

    Article  CAS  PubMed  Google Scholar 

  11. Siegel R, Hauschild A, Kettelhack C, Kahler KC, Bembenek A, Schlag PM. Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma. Eur J Surg Oncol. 2007;33:627–32.

    Article  CAS  PubMed  Google Scholar 

  12. Voelter V, Schalenbourg A, Pampallona S, Peters S, Halkic N, Denys A, Goitein G, Zografos L, Leyvraz S. Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients. Melanoma Res. 2008;18:220–4.

    Article  CAS  PubMed  Google Scholar 

  13. Farolfi A, Ridolfi L, Guidoboni M, Milandri C, Calzolari F, Scarpi E, Amadori D, Ridolfi R. Liver metastases from melanoma: hepatic intra-arterial chemotherapy. A retrospective study. J Chemother. 2011;23:300–5.

    Article  CAS  PubMed  Google Scholar 

  14. Heusner TA, Antoch G, Wittkowski-Sterczewski A, Ladd SC, Forsting M, Verhagen R, Scheulen M. Transarterial hepatic chemoperfusion of uveal melanoma metastases: survival and response to treatment. Rofo. 2011;183:1151–60.

    Article  PubMed  Google Scholar 

  15. Mavligit GM, Charnsangavej C, Carrasco CH, Patt YZ, Benjamin RS, Wallace S. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA. 1988;260:974–6.

    Article  CAS  PubMed  Google Scholar 

  16. Patel K, Sullivan K, Berd D, Mastrangelo MJ, Shields CL, Shields JA, Sato T. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res. 2005;15:297–304.

    Article  PubMed  Google Scholar 

  17. Sato T, Eschelman DJ, Gonsalves CF, Terai M, Chervoneva I, McCue PA, Shields JA, Shields CL, Yamamoto A, Berd D, Mastrangelo MJ, Sullivan KL. Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 2008;26:5436–42.

    Article  CAS  PubMed  Google Scholar 

  18. Schuster R, Lindner M, Wacker F, Krossin M, Bechrakis N, Foerster MH, Thiel E, Keilholz U, Schmittel A. Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome. Melanoma Res. 2010;20:191–6.

    CAS  PubMed  Google Scholar 

  19. Fiorentini G, Aliberti C, Del Conte A, Tilli M, Rossi S, Ballardini P, Turrisi G, Benea G. Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study. In Vivo. 2009;23:131–7.

    PubMed  Google Scholar 

  20. Pingpank JF, Libutti SK, Chang R, Wood BJ, Neeman Z, Kam AW, Figg WD, Zhai S, Beresneva T, Seidel GD, Alexander HR. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol. 2005;23:3465–74.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Cocconi G, Gamboni A, Gasparro D, Leonardi F, Salvagni S, Vasini G, Larini P, Marcato C, Camisa R, Cascinu S. Hepatic artery administration of docetaxel in liver metastases from breast carcinoma: a feasibility study. Tumori. 2005;91:121–5.

    CAS  PubMed  Google Scholar 

  22. Giroux MF, Baum RA, Soulen MC. Chemoembolization of liver metastasis from breast carcinoma. J Vasc Interv Radiol. 2004;15:289–91.

    Article  PubMed  Google Scholar 

  23. Li XP, Meng ZQ, Guo WJ, Li J. Treatment for liver metastases from breast cancer: results and prognostic factors. World J Gastroenterol. 2005;11:3782–7.

    PubMed  Google Scholar 

  24. Vogl TJ, Naguib NN, Nour-Eldin NE, Mack MG, Zangos S, Abskharon JE, Jost A. Repeated chemoembolization followed by laser-induced thermotherapy for liver metastasis of breast cancer. AJR Am J Roentgenol. 2011;196:W66–72.

    Article  PubMed  Google Scholar 

  25. Duan XF, Dong NN, Zhang T, Li Q. Treatment outcome of patients with liver-only metastases from breast cancer after mastectomy: a retrospective analysis. J Cancer Res Clin Oncol. 2011;137:1363–70.

    Article  CAS  PubMed  Google Scholar 

  26. Nabil M, Gruber T, Yakoub D, Ackermann H, Zangos S, Vogl TJ. Repetitive transarterial chemoembolization (TACE) of liver metastases from renal cell carcinoma: local control and survival results. Eur Radiol. 2008;18:1456–63.

    Article  PubMed  Google Scholar 

  27. Abdelmaksoud MH, Louie JD, Hwang GL, Kothary N, Minor DR, Sze DY. Yttrium-90 radioembolization of renal cell carcinoma metastatic to the liver. J Vasc Interv Radiol. 2012;23:323–30.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastrointestinal Cancer Unit, Institut Gustave Roussy, Gustave Roussy Cancer Campus, Paris, Villejuif, France

    Michel Ducreux

Authors
  1. Michel Ducreux
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michel Ducreux .

Editor information

Editors and Affiliations

  1. Department of Oncology, University Hospital Gasthuisberg Leuven Cancer Institute, Leuven, Belgium

    Eric Van Cutsem

  2. Department of Diagostic Radiology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany

    Thomas J. Vogl

  3. Department of Radiology, European Institute of Oncology, Milano, Italy

    Franco Orsi

  4. Department of Medical Oncology, IRCCS Ospedale San Martino IST, Genova, Italy

    Alberto Sobrero

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Ducreux, M. (2015). Liver Metastases of Other Indications. In: Van Cutsem, E., Vogl, T., Orsi, F., Sobrero, A. (eds) Locoregional Tumor Therapy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-36572-0_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-36572-0_7

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-36571-3

  • Online ISBN: 978-3-642-36572-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation